Literature DB >> 10850404

Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.

R Jelliffe1, D Bayard, M Milman, M Van Guilder, A Schumitzky.   

Abstract

Multiple model (MM) design and stochastic control of dosage regimens permit essentially full use of all the information contained in either a Bayesian prior nonparametric EM (NPEM) population pharmacokinetic model or in an MM Bayesian posterior updated parameter set, to achieve and maintain selected therapeutic goals with optimal precision (least predicted weighted squared error). The regimens are visibly more precise in the achievement of desired target goals than are current methods using mean or median population parameter values. Bayesian feedback has now also been incorporated into the MM software. An evaluation of MM dosage design using an NPEM population model versus dosage design based on conventional mean population parameter values is presented, using a population model of vancomycin. Further feedback control was also evaluated, incorporating realistic simulated uncertainties in the clinical environment such as those in the preparation and administration of doses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10850404     DOI: 10.1097/00007691-200006000-00018

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  31 in total

1.  Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Authors:  Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

2.  Impact of sample size on the performance of multiple-model pharmacokinetic simulations.

Authors:  Vincent H Tam; Samer Kabbara; Rosa F Yeh; Robert H Leary
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

3.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

4.  Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools.

Authors:  Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

Review 5.  Pharmacokinetics-Based Approaches for Bioequivalence Evaluation of Topical Dermatological Drug Products.

Authors:  Sam G Raney; Thomas J Franz; Paul A Lehman; Robert Lionberger; Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

6.  Optimal methodology is important for optimal pharmacokinetic studies, therapeutic drug monitoring and patient care.

Authors:  Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

7.  Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.

Authors:  Annick Rousseau; Christophe Sabot; Nicole Delepine; Gerard Delepine; Jean Debord; Gerard Lachâtre; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance.

Authors:  Roger W Jelliffe; Alan Schumitzky; David Bayard; Xiaowei Fu; Michael Neely
Journal:  Ther Drug Monit       Date:  2015-06       Impact factor: 3.681

Review 9.  Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy.

Authors:  Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

10.  Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.

Authors:  Siew Hua Gan; Rusli Ismail; Wan Aasim Wan Adnan; Wan Zulmi
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.